Your browser doesn't support javascript.
loading
Methods and results of locoregional treatment of brain metastases in patients with non-small cell lung cancer.
Patla, Anna; Walasek, Tomasz; Jakubowicz, Jerzy; Blecharz, Pawel; Mitus, Jerzy Wladyslaw; Mucha-Malecka, Anna; Reinfuss, Marian.
Afiliación
  • Patla A; Department of Radiotherapy, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Krakow Branch, Poland.
  • Walasek T; Department of Radiotherapy, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Krakow Branch, Poland.
  • Jakubowicz J; Department of Oncology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Krakow Branch, Poland.
  • Blecharz P; Department of Gynaecological Oncology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Krakow Branch, Poland.
  • Mitus JW; Department of Surgical Oncology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Krakow Branch, Poland.
  • Mucha-Malecka A; Department of Oncology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Krakow Branch, Poland.
  • Reinfuss M; Department of Radiotherapy, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Krakow Branch, Poland.
Contemp Oncol (Pozn) ; 20(5): 358-364, 2016.
Article en En | MEDLINE | ID: mdl-28373816
ABSTRACT
This article presents methods and results of surgery and radiotherapy of brain metastases from non-small cell lung cancer (BMF-NSCLC). Patients with single BMF-NSCLC, with Karnofsky score ≥ 70 and controlled extracranial disease are the best candidates for surgery. Stereotactic radiosurgery (SRS) is recommended in patients with 1-3 BMF-NSCLC below 3-3.5 cm, with minor neurological symptoms, located in parts of the brain not accessible to surgery, with controlled extracranial disease. Whole brain radiotherapy (WBRT) following SRS reduces the risk of local relapse; in selected patients median survival reaches more than 10 months. Whole brain radiotherapy alone is a treatment in patients with multiple metastases, poor performance status, uncontrolled extracranial disease, disqualified from surgery or SRS with median survival 3 to 6 months. There is no doubt that there are patients with BMF-NSCLC who should receive only the best supportive care. There is a debate in the literature on how to select these patients.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Contemp Oncol (Pozn) Año: 2016 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Contemp Oncol (Pozn) Año: 2016 Tipo del documento: Article